Is Mankind Pharma (MANKIND) overvalued or fairly valued?

MarketChacha shows Mankind Pharma's valuation in context — a forward P/E of about 34.0, a price-to-book of about 6.1 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Mankind Pharma's revenue?

Mankind Pharma reported revenue of ₹10,421 Cr for FY2026, with net profit of ₹2,038 Cr, per official filings.

What is the share price of Mankind Pharma (MANKIND)?

Mankind Pharma last traded at ₹2,394.00 (+0.6% on the day), as of 8/19/2026 — a delayed quote shown for education, not investment advice.

Mankind Pharma

MANKIND · NSE · Pharma · India

Snapshot

TickerMANKIND

ExchangeNSE

SectorPharma

IndustryDrug Manufacturers - Specialty & Generic

CountryIndia

Employees20,451

HeadquartersNew Delhi, India

Websitewww.mankindpharma.com

Filings tracked4

About Mankind Pharma

Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, urology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory, and other diseases. It also provides consumer healthcare products, such as condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. In addition, the company engages in the trading of pharmaceutical and health care products; manufacture of packing materials, ayurvedic products, and consumer goods; real estate, leasing, and hospitality businesses; trading of agricultural and pet food products; and provision of IT services. It offers its products under the Manforce, Moxi Kind-Cv, AmLokind-At, Unwanted-Kit, Prega News, Dydroboon, Telmikind-Am, Gudcef, Glimestar-M, Candi Force, Nurokind-Gold, Telmikind-H, Telmikind, Nurokind-Lc, Nurokind Plus-Rf, Vomikind, Cefakind, Glizid-M, Monticope, and Gudcef-Cv brand names. Mankind Pharma Limited was incorporated in 1991 and is based in New Delhi, India.

Who owns it

Promoters75.4%
Institutions19.7%
Public & other4.9%

177 institutional holders

Ownership breakdown from public market data. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend14.7% → 13.4%

Margin has held broadly steady over the period — stable profitability.

Growth qualityrev 13% · PAT 11%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹4,016 Cr · EPS 15.50

Est. earnings growth +29.3%

Next fiscal year

Rev ₹17,923 Cr · EPS 70.51

Est. earnings growth +23.1%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 5

Revenue (FY2026)

₹14,278 Cr

Net margin

13.4%

Revenue CAGR (3y)

+17.7%

Profit CAGR (3y)

+14.3%

Net profit (FY2026)

₹1,913 Cr

Ask MarketChacha about MANKIND

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹14,278 Cr	₹1,913 Cr	13.4%
FY2025	₹12,207 Cr	₹1,991 Cr	16.3%
FY2024	₹10,335 Cr	₹1,913 Cr	18.5%
FY2023	₹8,749 Cr	₹1,282 Cr	14.7%

Quarterly

Period	Revenue	Net profit	Net margin
Q1 FY27	₹4,031 Cr	₹568 Cr	14.1%
Q4 FY26	₹3,443 Cr	₹554 Cr	16.1%
Q3 FY26	₹3,567 Cr	₹409 Cr	11.5%
Q2 FY26	₹3,697 Cr	₹512 Cr	13.8%
Q1 FY26	₹3,570 Cr	₹438 Cr	12.3%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

Filings & announcements

2026

Completion Of Realignment Of Security Cover In Respect Of Non-Convertible Debentures And Consequent Release Of Pledged Shares Of Bharat Serums And Vaccines Limited
Completion of realignment of Security Cover in respect of Non-Convertible Debentures.
BSE8/17/2026
Updates on Acquisition
Please find attached intimation regarding incorporation of a wholly owned subsidiary company in Netherlands
BSE8/13/2026material
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Please find attached Voting Results and Scrutinizer''s Report of 35th AGM
BSE8/6/2026material
Final Update On Stake Sale Of Broadway Hospitality Services Private Limited
Intimation under Regulation 30 of the SEBI LODR
BSE7/27/2026

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.